Literature DB >> 1617964

Conditions for choosing between drug-induced and surgical abortions.

A Bachelot1, L Cludy, A Spira.   

Abstract

In France, pregnant women with amenorrhoea of no more than 49 days intending to terminate pregnancy can choose between a surgical abortion via vacuum aspiration under local or general anesthesia and a drug method combining Mifepristone orally administered (RU 486 degrees), with a prostaglandin analogue. This prospective survey was conducted to study the conditions under which women choose their abortion method, and to evaluate the acceptability of each method after the abortion. The data gathered from 488 women were analyzed according to their initial decision, and then according to the method actually used. The majority (62%) chose RU 486. The women's choice was found to be linked to sociodemographic characteristics such as age, education, occupation, geographic origin, and certain attitudes towards pregnancy, as well as to the individual criteria of each method. The women who chose the drug protocol had most often already made their decision before going to the family planning center (68%), having been advised by their doctor (20%). They were slightly less satisfied with the abortion experience than they had expected: 12.4% were unsatisfied in the RU group and 3.6% in the aspiration group. They needed more rest and quiet afterwards (50%) than the other women. They were distinguished by their desire to verify the expulsion (63%). The length of pregnancy is therefore not the only criterion to be considered when recommending one or other of these methods: the women concerned have different requirements and should have several possibilities to choose from.

Entities:  

Keywords:  Abortion, Drug Induced; Abortion, Induced; Age Factors--statistics; Anesthesia--administraction and dosage; Attitude; Behavior; Biology; Contraception; Contraceptive Usage; Data Analysis; Data Collection; Decision Making; Demographic Factors; Developed Countries; Economic Factors; Educational Status--statistics; Endocrine System; Europe; Family Planning; Fertility; Fertility Control, Postconception; Fertility Measurements; France; Hormone Antagonists; Hormones; Human Resources; Mediterranean Countries; Method Acceptability; Occupations--statistics; Physiology; Population; Population Characteristics; Population Dynamics; Pregnancy History; Prospective Studies; Prostaglandins--administraction and dosage; Psychological Factors; Research Methodology; Ru-486--administraction and dosage; Satisfaction; Socioeconomic Factors; Socioeconomic Status; Statistical Regression; Studies; Treatment; Vacuum Aspiration; Western Europe

Mesh:

Substances:

Year:  1992        PMID: 1617964     DOI: 10.1016/0010-7824(92)90106-4

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  6 in total

1.  Medical vs. surgical abortion: the importance of women's choice.

Authors:  Caroline Moreau; James Trussell; Julie Desfreres; Nathalie Bajos
Journal:  Contraception       Date:  2011-02-25       Impact factor: 3.375

Review 2.  Medical methods for first trimester abortion.

Authors:  Jing Zhang; Kunyan Zhou; Dan Shan; Xiaoyan Luo
Journal:  Cochrane Database Syst Rev       Date:  2022-05-24

Review 3.  Pain management for medical abortion before 14 weeks' gestation.

Authors:  John J Reynolds-Wright; Mulat A Woldetsadik; Chelsea Morroni; Sharon Cameron
Journal:  Cochrane Database Syst Rev       Date:  2022-05-13

4.  Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment.

Authors:  R C Henshaw; S A Naji; I T Russell; A A Templeton
Journal:  BMJ       Date:  1993-09-18

5.  Abortion induced with methotrexate and misoprostol.

Authors:  E R Wiebe
Journal:  CMAJ       Date:  1996-01-15       Impact factor: 8.262

Review 6.  Medical methods for first trimester abortion.

Authors:  Regina Kulier; Nathalie Kapp; A Metin Gülmezoglu; G Justus Hofmeyr; Linan Cheng; Aldo Campana
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.